Medicines Development sets its sights on a PRV

November 13, 2014

Priority Review Voucher

Medicines Development is working on the registration of a new game changing treatment for river blindness and scabies. According to the current legislation, with the registration of the new treatment MDL will be eligible for a Priority Review Voucher from the FDA.

See details on the FDA voucher scheme.